REG - Ondine Biomedical - Ondine Appoints Peel Hunt as Broker

Ondine BiomedicalAnnouncement

01/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nRSA0870Pa&default-theme=true

RNS Number : 0870P  Ondine Biomedical Inc.  01 July 2025

1 July 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Ondine Appoints Peel Hunt as Broker and Joint Financial Adviser

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces the appointment of Peel
Hunt LLP as the Company's broker and joint financial adviser, effective
immediately.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"We are pleased to be working with Peel Hunt, a firm with deep expertise in
supporting growth-stage companies in the healthcare sector. Their strong
investor network and integrated advisory approach will help us expand our
shareholder base and strengthen investor support as we continue to grow our
business globally."

About Peel Hunt

Peel Hunt is a leading UK investment bank that specialises in supporting
mid-cap and growth companies. It provides integrated investment banking advice
and services to UK corporates, including equity capital markets, private
capital markets, M&A, debt advisory, investor relations and corporate
broking. The Company's joined up approach combines these services with expert
research and distribution and an execution services hub that provides
liquidity to the UK capital markets, delivering value to global institutions
and trading counterparties alike. The Company is admitted to trading on AIM
(LON: PEEL) and has offices in London, New York and Copenhagen.

 Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com (http://www.ondinebio.com)
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave®. In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKKBBKBKBNAN